AGENUS INC (AGEN) Stock News
NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD
AGEN Latest News, Press Relases and Analysis
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates
Vertex (VRTX) delivered earnings and revenue surprises of -3.79% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VRTX
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ADCT
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Mentions: ANIP
Enphase Energy Stock Sinks on Weaker-Than-Expected Results, Expected Tariffs Hit
Shares of Enphase Energy fell sharply in premarket trading Wednesday, a day after the solar and battery systems provider's first-quarter results fell short of analysts' estimates and it warned of an expected hit to gross margins because of tariffs on China.
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
Agenus (AGEN) Q4 2024 Earnings Call Transcript
AGEN earnings call for the period ending December 31, 2024.
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus (AGEN) Q3 2024 Earnings Call Transcript
AGEN earnings call for the period ending September 30, 2024.
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
Shareholders that lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about pending Class Action - AGEN
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS...
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during...